These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 16611201)

  • 1. Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction.
    Hernández-Díaz S; Varas-Lorenzo C; García Rodríguez LA
    Basic Clin Pharmacol Toxicol; 2006 Mar; 98(3):266-74. PubMed ID: 16611201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease.
    Ray WA; Varas-Lorenzo C; Chung CP; Castellsague J; Murray KT; Stein CM; Daugherty JR; Arbogast PG; García-Rodríguez LA
    Circ Cardiovasc Qual Outcomes; 2009 May; 2(3):155-63. PubMed ID: 20031832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis.
    Schneeweiss S; Solomon DH; Wang PS; Rassen J; Brookhart MA
    Arthritis Rheum; 2006 Nov; 54(11):3390-8. PubMed ID: 17075817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction.
    Kimmel SE; Berlin JA; Reilly M; Jaskowiak J; Kishel L; Chittams J; Strom BL
    Ann Intern Med; 2005 Feb; 142(3):157-64. PubMed ID: 15684203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2.
    McGettigan P; Henry D
    JAMA; 2006 Oct; 296(13):1633-44. PubMed ID: 16968831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials.
    Chen LC; Ashcroft DM
    Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):762-72. PubMed ID: 17457957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
    Rahme E; Nedjar H
    Rheumatology (Oxford); 2007 Mar; 46(3):435-8. PubMed ID: 17255138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study.
    Rahme E; Watson DJ; Kong SX; Toubouti Y; LeLorier J
    Pharmacoepidemiol Drug Saf; 2007 May; 16(5):493-503. PubMed ID: 17086567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study.
    Graham DJ; Campen D; Hui R; Spence M; Cheetham C; Levy G; Shoor S; Ray WA
    Lancet; 2005 Feb 5-11; 365(9458):475-81. PubMed ID: 15705456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.
    Gislason GH; Jacobsen S; Rasmussen JN; Rasmussen S; Buch P; Friberg J; Schramm TK; Abildstrom SZ; Køber L; Madsen M; Torp-Pedersen C
    Circulation; 2006 Jun; 113(25):2906-13. PubMed ID: 16785336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of non-steroidal anti-inflammatory drugs correlates with the risk of venous thromboembolism in knee osteoarthritis patients: a UK population-based case-control study.
    Lee T; Lu N; Felson DT; Choi HK; Dalal DS; Zhang Y; Dubreuil M
    Rheumatology (Oxford); 2016 Jun; 55(6):1099-105. PubMed ID: 26983451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population.
    García Rodríguez LA; Varas-Lorenzo C; Maguire A; González-Pérez A
    Circulation; 2004 Jun; 109(24):3000-6. PubMed ID: 15197149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
    Valat JP; Deray G; Héloire F
    Presse Med; 2006 Sep; 35(9 Spec No 1):1S25-34. PubMed ID: 17078592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of acute myocardial infarction during use of individual NSAIDs: A nested case-control study from the SOS project.
    Masclee GMC; Straatman H; Arfè A; Castellsague J; Garbe E; Herings R; Kollhorst B; Lucchi S; Perez-Gutthann S; Romio S; Schade R; Schink T; Schuemie MJ; Scotti L; Varas-Lorenzo C; Valkhoff VE; Villa M; Sturkenboom MCJM
    PLoS One; 2018; 13(11):e0204746. PubMed ID: 30383755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cause-specific cardiovascular risk associated with nonsteroidal anti-inflammatory drugs among myocardial infarction patients--a nationwide study.
    Olsen AM; Fosbøl EL; Lindhardsen J; Andersson C; Folke F; Nielsen MB; Køber L; Hansen PR; Torp-Pedersen C; Gislason GH
    PLoS One; 2013; 8(1):e54309. PubMed ID: 23382889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
    ; Bhala N; Emberson J; Merhi A; Abramson S; Arber N; Baron JA; Bombardier C; Cannon C; Farkouh ME; FitzGerald GA; Goss P; Halls H; Hawk E; Hawkey C; Hennekens C; Hochberg M; Holland LE; Kearney PM; Laine L; Lanas A; Lance P; Laupacis A; Oates J; Patrono C; Schnitzer TJ; Solomon S; Tugwell P; Wilson K; Wittes J; Baigent C
    Lancet; 2013 Aug; 382(9894):769-79. PubMed ID: 23726390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study.
    Johnsen SP; Larsson H; Tarone RE; McLaughlin JK; Nørgård B; Friis S; Sørensen HT
    Arch Intern Med; 2005 May; 165(9):978-84. PubMed ID: 15883235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does the varied use of NSAIDs explain the differences in the risk of myocardial infarction?
    van Staa TP; Rietbrock S; Setakis E; Leufkens HG
    J Intern Med; 2008 Nov; 264(5):481-92. PubMed ID: 18624902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies.
    McGettigan P; Henry D
    PLoS Med; 2011 Sep; 8(9):e1001098. PubMed ID: 21980265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly.
    Mamdani M; Rochon P; Juurlink DN; Anderson GM; Kopp A; Naglie G; Austin PC; Laupacis A
    Arch Intern Med; 2003 Feb; 163(4):481-6. PubMed ID: 12588209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.